Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Moleculin Biotech ( (MBRX) ).
On January 27, 2025, Moleculin Biotech announced the launch of its MIRACLE pivotal study for second line relapsed/refractory acute myeloid leukemia (AML), marking a significant milestone in its drug development efforts. The company has made substantial progress in preparing for this global registration trial, including selecting over 25 clinical sites and expecting to activate over 70, with the first patient anticipated to be treated within the first quarter. The trial aims to complete the 90-patient Part A by early 2026. Moleculin’s drug Annamycin shows promising preliminary results, outpacing competitors, and is generating increased interest from potential partners, reflecting its potential impact on the AML treatment landscape.
More about Moleculin Biotech
Moleculin Biotech is a company operating in the biotechnology industry, primarily focused on developing treatments for various cancers. Their key market focus is on innovative therapies for acute myeloid leukemia (AML), with their products being listed and traded on Nasdaq under the ticker MBRX.
YTD Price Performance: -3.95%
Average Trading Volume: 55,759
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.42M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.
